Gradient Investments LLC Grows Stock Holdings in Abbott Laboratories $ABT

Key Points

• Gradient Investments LLC increased its stake in Abbott Laboratories by 15.7% in Q4 to 346,541 shares, worth about $43.4 million.
• Abbott reported Q4 EPS of $1.50 (in line with estimates) and revenue of $11.46 billion (up 4.4% YoY but below consensus), and provided Q1 2026 guidance of 1.120–1.180 EPS and FY 2026 guidance of 5.550–5.800 EPS.
• The board declared a quarterly dividend of $0.63 (annualized $2.52, ~2.4% yield), while analysts maintain a consensus rating of "Moderate Buy" with a consensus target price of $136.16.

Gradient Investments LLC increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 15.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 346,541 shares of the healthcare product maker's stock after buying an additional 47,135 shares during the period. Gradient Investments LLC's holdings in Abbott Laboratories were worth $43,418,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Charles Schwab Trust Co grew its holdings in Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker's stock valued at $3,939,000 after buying an additional 15,394 shares in the last quarter. Asset Management One Co. Ltd. lifted its holdings in shares of Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker's stock worth $115,032,000 after buying an additional 19,966 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of Abbott Laboratories by 6.1% in the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker's stock worth $43,785,000 after buying an additional 18,974 shares in the last quarter. AE Wealth Management LLC boosted its position in shares of Abbott Laboratories by 20.8% during the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker's stock worth $8,774,000 after acquiring an additional 11,264 shares during the last quarter. Finally, Mawer Investment Management Ltd. grew its stake in Abbott Laboratories by 5.9% during the third quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker's stock valued at $168,199,000 after acquiring an additional 70,122 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $105.58 on Monday. The company's 50-day moving average price is $112.75 and its 200-day moving average price is $122.97. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The company has a market cap of $183.88 billion, a PE ratio of 28.38, a price-to-earnings-growth ratio of 1.68 and a beta of 0.74. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts' consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 EPS. The firm's revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories's payout ratio is 67.74%.

Wall Street Analysts Forecast Growth

Several analysts have commented on ABT shares. BTIG Research decreased their price target on shares of Abbott Laboratories from $145.00 to $140.00 and set a "buy" rating on the stock in a research note on Tuesday, February 17th. Evercore reduced their target price on Abbott Laboratories from $144.00 to $138.00 and set an "outperform" rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group decreased their target price on Abbott Laboratories from $136.00 to $113.00 and set an "outperform" rating on the stock in a research report on Friday, January 30th. Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an "outperform" rating for the company in a report on Friday, January 23rd. Finally, The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $152.00 to $140.00 and set a "buy" rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $136.16.

Insider Activity

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.